IL17A and rheumatoid arthritis: (1) Protective: reduce cell death; inhibiting IL-1β-induced MMP synthesis by RA FLS; inhibit Th17 cell development and function.(2) Pathogenic: activate IL-17 induced pathology or directly effects skin and bone cells in PsA; drive tissue remodeling in RA.